Description
This product utilizes CD8+ T cells that have been engineered with our proprietary GeneCircuit technology to specifically target CD22 ( clone IRO314). We employs the HBV (trc-GFP-IL-4-KpnI) vector components and the SynExpress system of the miRNA Knockout/Negative feedback for a robust and sustained response against cancers.
Host
Humanized
Target
CD22
Clone
IRO314
Species Reactivity
Human
Cell Source
Modified CD8+ T cells
Sensor Gene
GFP
Promoter
trc
Effector Gene
IL-4
Insertion Sites
KpnI
Gene Modification
Knockout
Modification Domain
miRNA
Carrier Type
HBV
Transformation Accuracy
0.92
Cell Culture
Aseptic Culture

For Research Use Only | Not For Clinical Use

Online Inquiry
Related Products
Copyright © 2025 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.